About burosumab
Anti-FGF23 monoclonal antibody
Used for
- Treats X-linked hypophosphatemia in adults and children aged 6 months and older.
- Treats tumor-induced osteomalacia in adults and children aged 2 years and older.
Usual adult dose
X-linked hypophosphatemia: 1 mg/kg every 4 weeks, maximum 90 mg. Tumor-induced osteomalacia: 0.5 mg/kg every 4 weeks; dose may be adjusted.
Usual dose in children
X-linked hypophosphatemia, age 6 months and older: 0.8 mg/kg every 2 weeks, adjusted by blood phosphate. Tumor-induced osteomalacia, age 2 years and older: 0.4 mg/kg every 2 weeks, adjusted as needed.
Common side effects
- Injection-site reactions
- Headache
- Restless legs syndrome
- High blood phosphate or calcium
Important warnings
- Can cause high blood phosphate and kidney calcification.
- Do not use with oral phosphate or active vitamin D medicines.
- Check blood phosphate and kidney function during treatment.
- Avoid use in severe kidney impairment.
Pregnancy
Human pregnancy information is limited; use only when clearly needed and under specialist supervision.
Breastfeeding
It is unknown whether burosumab passes into breast milk; discuss risks with a healthcare professional.
Interactions
- Oral phosphate and active vitamin D analogues increase high-phosphate risk and should not be used together.
- Medicines that raise blood phosphate may increase risk of hyperphosphatemia.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.